13 September 2013

Smith & Nephew releases new DURAFIBER◊ Ag dressing to address bacterial contamination

Smith & Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the US introduction of DURAFIBER Ag antimicrobial gelling fiber dressing.  This new offering in the DURAFIBER portfolio combines the highly absorbent, gelling fiber filler dressing with the benefits of silver (Ag).  The addition of this broad-spectrum antimicrobial provides clinicians with a different approach to address bacterial contamination posed by medium to heavily exuding wounds.

“DURAFIBER Ag is strong when wet – a key attribute for ease of use for gelling fiber dressings” says Robin Carlstein, Interim President North America, Advanced Wound Management. “US Clinicians will now have the effective exudate management and anti-shrinkage properties of the DURAFIBER dressings with the addition of a broad-spectrum antimicrobial. The DURAFIBER portfolio facilitates clean, cost-effective, one-piece dressing removal continuing on the Smith & Nephew commitment to deliver consistent clinical and economic benefits for wound care.” 

For more information about DURAFIBER and DURAFIBER Ag, visit www.DURAFIBERAg.com


Beth Bentley
Smith & Nephew

Phil Cowdy
+44 (0) 20 7401 7646
Smith & Nephew 

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma, Smith & Nephew has around 11,000 employees and a presence in more than 90 countries. Annual sales in 2012 were more than $4.1 billion. Smith & Nephew is a member of the FTSE100 (LSE: SN, NYSE: SNN).

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payors and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; strategic actions, including acquisitions and dispositions, our success in integrating acquired businesses, and disruption that may result from changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors.

Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.  

◊ Trademark of Smith & Nephew.  Certain marks registered US Patent and Trademark Office.